Please provide your email address to receive an email when new articles are posted on . Amivantamab-vmjw plus lazertinib significantly improved OS for certain patients with advanced NSCLC compared ...
Powerhouse NHL teams are often built on the foundation of star forwards. This has been true for recent Stanley Cup winners like the Avalanche and Lightning. Vegas’ top line may not have been ...
Adding tucatinib (Tukysa) to first-line maintenance therapy with trastuzumab (Herceptin) and pertuzumab (Perjeta) delayed disease progression in patients with HER2-positive metastatic breast cancer, ...
Please provide your email address to receive an email when new articles are posted on . Fixed-duration acalabrutinib plus venetoclax improved outcomes for untreated chronic lymphocytic leukemia ...
Understanding the patterns of acquired resistance to epidermal growth factor receptor (EGFR) TKI treatment has led to more effective combination therapy and continues to drive development of novel ...
Lenvima plus Keytruda did not significantly improve survival or progression-free survival compared to chemotherapy in advanced endometrial cancer. The study involved 842 patients, with no new safety ...
Tislelizumab, combined with chemotherapy, is now FDA-approved for first-line treatment of unresectable or metastatic ESCC with PD-L1 expression. The phase 3 RATIONALE-306 study demonstrated ...
In the first phase 3 trial to show the superiority of a TROP2-targeted antibody-drug conjugate and an immunotherapy agent in first-line triple-negative breast cancer (TNBC), Gilead Sciences’ Trodelvy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results